Abstract
Between 1960 and 1982, the National Cancer Institute (NCI) screened over 180,000 microbial-derived, some 16,000 marine organism-derived, and over 114,000 plant-derived extracts. A number of clinically effective chemotherapeutic agents were developed, mainly through collaborative efforts with the public and private sectors. These agents include paclitaxel, camptothecin derivatives, various anthracyclines, bleomycin, actinomycin and mitomycin. Since 1986, collections of plants and marine invertebrates have been performed in over 25 tropical and subtropical countries worldwide through contracts with botanical and marine biological organizations, working in close collaboration with source country organizations and subject to agreements with the source country authorities. Over 120,000 extracts are stored at low temperatures in the NCI Natural Products Repository and are made available to the scientific community for testing in screens related to all human diseases, subject to the signing of Material Transfer Agreements, which protects the rights of all parties, particularly those of the source countries. In addition, Memoranda of Understanding (MOU) have been signed with qualified organizations in over ten source countries for direct collaboration in the drug discovery and development process. A major goal of these collaborations is to promote drug discovery in the source country, with NCI collaborating in the preclinical and clinical development stages.
Author to whom enquiries should be addressed
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
J. T. Baker, R. P. Bonis, B. Carte, G. M. Cragg, M. P. Gupta, M. M. Iwu, D. R. Madulid, V. E. Tyler. Natural product drug discovery and development: new perspectives on international collaboration. J Nat Prod. 58, 1325–1357 (1995).
M. R. Boyd, K. D. Paull: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91–109, 1995.
B.K. Carte. Biomedical Potential of Marine Natural Products. Bio-Science 46, 271–286 (1996).
M. C. Christian, J. M. Pluda, T.C. Ho, S.G. Arbuck, A. J Murgo, E. A. Sausville. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Sem. Oncol. 24, 219–240 (1997).
R.R. Colwell. Microbial diversity: the importance of exploration and conservation. J. Ind. Microbiol. & Biotech. 18, 302–307 (1997).
J. E. Cortes, R. Pazdur. Docetaxel. J. Clin. Oncol. 13 2643–2655 (1995).
G. M. Cragg, M. R. Boyd, J. H. Cardellina II, M. R. Grever, S. A. Schepartz, K.M. Snader, M. Suffhess. Role of plants in the National Cancer Institute drug discovery and development program. In: Human Medicinal Agents from Plants. In Human Medicinal Agents from Plants. Am. Chem. Soc. Symposium Series (AD Kinghorn, MF Balandrin, eds.), Vol. 534, pp. 80–95. Amer. Chem. Soc, Washington, DC (1993).
G. M.Cragg, M. R. Boyd, J. H. Cardellina II, D. J. Newman, K. M. Snader, T. G. McCloud. Ethnobotany and the Search for New Drugs. In Ethnobotany and the Search for New Drugs. Ciba Foundation Symposium, (DJ Chadwick, J Marsh, eds.), Vol. 185, pp. 178–196. Wiley & Sons, Chichester, U.K. (1994).
Cragg, G.M., Boyd, M.R., Khanna, R., Newman, D.J., and Sausville, E.A., Natural Products Drug Discovery and Development. The United States National Cancer Institute Role. In: Phytochemicals in Human Health Protection, Nutrition and Plant Defense, Romeo, (ed.), Kluwer Academic/Plenum Publishers, New York, pp. 1–29 (1999).
G. M.Cragg, D. J. Newman, K. M. Snader. Natural Products in Drug Discovery and Development. J. Nat. Prod. 60, 52–60 (1997).
G. M. Cragg, S. A. Schepartz, M. Suffhess, M. R. Grever. The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J. Nat. Prod. 56, 1657–1668, (1993).
M. T. Flavin, J. D. Rizzo, A. Khilevich, A. Kucherenko,. A. K. Sheinkman, V. Vilaychack,. L. Lin,. W. Chen, E.M. Greenwood, T. Pengsuparp,. J. Pezzuto, S.H. Hughes, T. M. Flavin,, M. Cibulski, W. A. Boulanger,. R.L. Shone,. Z.-Q. Xu. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+)-calanolide A and its enantiomers. J. Med. Chem. 39, 1303–1313(1996).
W. O. Foye. Cancer Chemotherapeutic Agents, ACS Professional Reference Book, Amer. Chem. Soc, Washington, D. C. (1995).
J. L. Hartwell. Plants Used Against Cancer, Quarterman, Lawrence, Massachusetts (1982).
L.D. Kapoor. CRC Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton, Florida (1990).
Y. Kashman, K. R. Gustafson, R. W. Fuller, J. H. Cardellina, II, J. B. McMahon, M. J. Currens, R. W. Buckheit, S. H Hughes, G. M. Cragg, M. R. Boyd. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem. 35, 2735–2743 (1992).
B. H. Long, J. M. Carboni, A. J. Wasserman, L. A. Cornell, A. M. Casazza, P. R. Jensen, T. Lindel, W. Fenical, C. R. Fairchild. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel. Cancer Research 58, 1111–1115 (1998).
T. D. Mays, K. D. Mazan, G. M. Cragg, M. R. Boyd. “Triangular Privity” - a working paradigm for the equitable sharing of benefits from biodiversity research and development. In Global Genetic Resources: Access, Ownership, and Intellectual Property Rights, (KE Hoagland & AY Rossman, eds.), pp. 279–298. Association of Systematics Collections,, Washington, D.C. (1997).
O. McConnell, R. E. Longley, F. E. Koehn. The discovery of marine natural products with therapeutic potential. In The Discovery of Natural Products with Therapeutic Potential (V. P. Gullo, ed.), pp. 109–174. Butterworth-Heinemann, Boston, (1994).
R. G. Naik, S. L. Kattige, S. V. Bhat, B. Alreja, N. J. de Sousa, R. H. Rupp. An antiflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: Isolation, structure, and total synthesis. Tetrahedron 44, 2081–2086 (1988).
K. C. Nicolaou, F. Roschangar, D. Vourloumis. Chemical Biology of the Epothilones. Angew. Chem. Int. 37, 2014–2045 (1998).
P. A. Philip, D. Rea, P. Thavasu, J. Carmichel, N. S. A. Stuart, H. Rockett, D. C. Talbot, T. Ganesan, G. R. Pettit, F. Balkwill, A. L. Harris. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. 85, 1812–1818 (1993).
M. Potmeisel, H. Pinedo. Camptothecins: New Anticancer Agents. CRC Press, Boca Raton, Florida (1995).
K. Ten Kate, A. Wells. Benefit-Sharing Case Study. The access and benefit-sharing policies of the United States National Cancer Institute: a comparative account of the discovery and development of the drugs Calanolide and Topotecan. Submission to the Executive Secretary of the Convention on Biological Diversity by the Royal Botanic Gardens, Kew (1998).
E. ter Haar, R. J. Kowalski, C. M. Lin, R. E. Longley, S. P. Gunasekera, H. S. Rosenkranz, B. W. Day. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35, 243–250 (1996).
M. J. Towle, K. A. Salvato, J. Burrow, et al., Highly Potent in vitro and in vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogs of Halichondrin B. Proceedings of the 91st. Annual Meeting of the American Society for Cancer Research. San Francisco, 1370 (2000).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cragg, G.M., Newman, D.J. (2001). Natural Products Drug Discovery and Development at the United States National Cancer Institute. In: Lin, Y. (eds) Drug Discovery and Traditional Chinese Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1455-8_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1455-8_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5562-5
Online ISBN: 978-1-4615-1455-8
eBook Packages: Springer Book Archive